the corresponding immediate release component.

c) While having an insubstantial effect on the area under the plasma concentration time curve (AUC) of the dose of the slow release component relative to the corresponding immediate release component.

21. **(WITHDRAWN)** A therapeutically effective amount of a pharmaceutical composition of claim 16 which allows a reduction in the dosing regimen of any of the individual agents for diabetic and its associated disorders.
22. **(WITHDRAWN)** A therapeutically effective amount of a pharmaceutical composition of claim 16 which allows a reduction in the dosing regimen of any of the individual agents for cardiovascular and its associated disorders.
23. **(WITHDRAWN)** The pharmaceutical formulation as defined in claim 16 in the form of one or more tablets.
24. **(WITHDRAWN)** The pharmaceutical formulation as defined in claim 16 in the form of one or more capsules.
25. **(WITHDRAWN)** The pharmaceutical formulation as defined in claim 16 in the form of one or more tablets and /or capsules.
26. **(WITHDRAWN)** The pharmaceutical composition of claim 16 wherein when tested for in-vitro release, around 30-50% of the drug is released for the slow release component within a period of about 2 to 3 hours and not less than 75% of the drug is released within a period maximum 24 hours.
27. **(WITHDRAWN)** A method of treating a disease with a pharmaceutical composition of claim 16 comprising administering a human in need of treatment for the said disease.
28. **(WITHDRAWN)** The pharmaceutical composition of claim 1 wherein the component A is a nitrate the component B is platelet inhibitor and the component C is an HMG-CoA inhibitor
29. **(WITHDRAWN)** The pharmaceutical composition of claim 28 wherein the component A is isosorbide mononitrate the component B is clopidogrel / aspirin and the component C is statin.

PAGE 3/3 * RCVD AT 5/7/2008 11:04:09 PM [Eastern Daylight Time] * SVR:USPTO-EFXRF-5/0 * DNIS:2738300 * CSID:703 550 0409 * DURATION (mm-ss):01-08